John A. Stalfort III - 02 Jun 2025 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
02 Jun 2025
Net transactions value
$0
Form type
4
Filing time
04 Jun 2025, 16:15:26 UTC
Previous filing
26 Nov 2024
Next filing
05 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stalfort John A III Director C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS /s/ Kamran Alam, Attorney-in-Fact 04 Jun 2025 0001709418

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award $0 +56,623 +5.2% $0.000000 1,155,224 02 Jun 2025 Direct F1
holding TSHA Common Stock 884,290 02 Jun 2025 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Stock Option (right to buy) Award $0 +113,246 $0.000000 113,246 02 Jun 2025 Common Stock 113,246 $2.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2 The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
F3 The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.